JP2023550485A5 - - Google Patents
Info
- Publication number
- JP2023550485A5 JP2023550485A5 JP2023530843A JP2023530843A JP2023550485A5 JP 2023550485 A5 JP2023550485 A5 JP 2023550485A5 JP 2023530843 A JP2023530843 A JP 2023530843A JP 2023530843 A JP2023530843 A JP 2023530843A JP 2023550485 A5 JP2023550485 A5 JP 2023550485A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- dsrna
- antisense
- positions
- sense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063117005P | 2020-11-23 | 2020-11-23 | |
| US63/117,005 | 2020-11-23 | ||
| PCT/US2021/060356 WO2022109398A1 (en) | 2020-11-23 | 2021-11-22 | Oligonucleotides for dgat2 modulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023550485A JP2023550485A (ja) | 2023-12-01 |
| JP2023550485A5 true JP2023550485A5 (enExample) | 2024-11-29 |
Family
ID=81709762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023530843A Pending JP2023550485A (ja) | 2020-11-23 | 2021-11-22 | Ｄｇａｔ２調節のためのオリゴヌクレオチド |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220228141A1 (enExample) |
| EP (1) | EP4247391A4 (enExample) |
| JP (1) | JP2023550485A (enExample) |
| AU (1) | AU2021382621A1 (enExample) |
| WO (1) | WO2022109398A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160319278A1 (en) | 2015-04-03 | 2016-11-03 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| WO2017030973A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| US10478503B2 (en) | 2016-01-31 | 2019-11-19 | University Of Massachusetts | Branched oligonucleotides |
| CA3033368A1 (en) | 2016-08-12 | 2018-02-15 | University Of Massachusetts | Conjugated oligonucleotides |
| JP7406793B2 (ja) | 2017-06-23 | 2023-12-28 | ユニバーシティー オブ マサチューセッツ | ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法 |
| US11279930B2 (en) | 2018-08-23 | 2022-03-22 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| CN113614232A (zh) | 2019-01-18 | 2021-11-05 | 马萨诸塞大学 | 动态药代动力学修饰锚 |
| KR20220047989A (ko) | 2019-08-09 | 2022-04-19 | 유니버시티 오브 매사추세츠 | Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드 |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| WO2021242883A1 (en) | 2020-05-26 | 2021-12-02 | University Of Massachusetts | Synthetic oligonucleotides having regions of block and cluster modifications |
| EP4181932A4 (en) * | 2020-07-16 | 2025-07-16 | Univ Massachusetts | CONJUGATED OLIGONUCLEOTIDES FOR SPECIFIC TISSUE DELIVERY |
| CN117677699A (zh) | 2021-06-23 | 2024-03-08 | 马萨诸塞大学 | 用于治疗先兆子痫和其他血管生成病症的优化抗flt1寡核苷酸化合物 |
| WO2024228030A2 (en) * | 2023-05-04 | 2024-11-07 | Argonaute RNA Limited | Dual silencing |
| KR20260006569A (ko) * | 2023-05-04 | 2026-01-13 | 아르고노트 알엔에이 리미티드 | 이중 발현 억제 |
| WO2024238752A1 (en) * | 2023-05-17 | 2024-11-21 | University Of Massachusetts | Oligonucleotides for dgat2, fasn, opn, and nox4 modulations |
| EP4722365A1 (en) * | 2023-05-26 | 2026-04-08 | Visirna Therapeutics (Suzhou) Co., Ltd. | Double-stranded nucleotide compound for metabolic diseases and use thereof |
| CN119464281A (zh) * | 2023-08-09 | 2025-02-18 | 北京福元医药股份有限公司 | 抑制DGAT2基因表达的siRNA、siRNA缀合物或其前药和药物组合物及用途 |
| WO2025040139A1 (zh) * | 2023-08-23 | 2025-02-27 | 云合智药（苏州）生物科技有限公司 | 用于抑制二酰甘油-O-酰基转移酶2表达的RNAi剂及其应用 |
| CN117257764A (zh) * | 2023-09-26 | 2023-12-22 | 中国药科大学 | 一种脂滴衍生的核酸药物递送系统及其制备方法和应用 |
| CN121825964A (zh) * | 2023-12-26 | 2026-04-10 | 苏州吉玛基因股份有限公司 | 用于抑制DGAT2的siRNA及其修饰物与应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003053363A2 (en) * | 2001-12-19 | 2003-07-03 | Millennium Pharmaceuticals, Inc. | Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US20190270995A1 (en) * | 2002-11-14 | 2019-09-05 | Thermo Fisher Scientific Inc. | Methods and Compositions for Selecting siRNA of Improved Functionality |
| US7825235B2 (en) * | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
| KR102234623B1 (ko) * | 2013-05-22 | 2021-04-02 | 알닐람 파마슈티칼스 인코포레이티드 | Ｔｍｐｒｓｓ6 조성물 및 이의 사용 방법 |
| RS62672B1 (sr) * | 2015-04-03 | 2021-12-31 | Univ Massachusetts | Oligonukleotidna jedinjenja za tretman preeklampsije i drugih angiogenskih poremećaja |
| MX2018000412A (es) * | 2015-07-10 | 2018-03-14 | Ionis Pharmaceuticals Inc | Moduladores de diaciglicerol aciltransferasa 2 (dgat2). |
| CA3164050A1 (en) * | 2019-12-09 | 2021-06-17 | Empirico Inc. | Oligonucleotides for treatment of angiopoietin like 4 (angptl4) related diseases |
| TW202221120A (zh) * | 2020-08-04 | 2022-06-01 | 美商黛瑟納製藥公司 | 用於治療代謝症候群之組成物及方法 |
-
2021
- 2021-11-22 US US17/532,636 patent/US20220228141A1/en active Pending
- 2021-11-22 AU AU2021382621A patent/AU2021382621A1/en active Pending
- 2021-11-22 EP EP21895761.1A patent/EP4247391A4/en active Pending
- 2021-11-22 WO PCT/US2021/060356 patent/WO2022109398A1/en not_active Ceased
- 2021-11-22 JP JP2023530843A patent/JP2023550485A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023550485A5 (enExample) | ||
| CN113164509B (zh) | 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法 | |
| JP2023522701A5 (enExample) | ||
| RU2566724C9 (ru) | Композиции и способы модуляции smn2 сплайсинга у субъекта | |
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| JP2022528487A5 (enExample) | ||
| JP2023534951A5 (enExample) | ||
| JP2016524588A (ja) | 治療用オリゴヌクレオチドを送達するための二本鎖剤 | |
| JP2023518268A5 (enExample) | ||
| EP4038191A1 (en) | Chemical modifications of small interfering rna with minimal fluorine content | |
| JP2023538283A (ja) | 代謝症候群の治療のための組成物及び方法 | |
| US20240401059A1 (en) | Compositions and methods for modulating pnpla3 expression | |
| EP3516062A1 (en) | Myostatin irna compositions and methods of use thereof | |
| JP2022517742A5 (enExample) | ||
| CN119768186A (zh) | 用于向cns组织递送治疗剂的脂质缀合物 | |
| WO2023208109A9 (zh) | 用于抑制HSD17B13表达的siRNA、其缀合物和药物组合物及其用途 | |
| US20230272393A1 (en) | Compositions and methods for modulating apoc3 expression | |
| CA3269248A1 (en) | COMPOSITIONS AND METHODS OF TREATMENT FOR NEUROLOGICAL DISORDERS | |
| WO2022184852A1 (en) | Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell | |
| JP7536187B2 (ja) | 核内受容体サブファミリー１グループｈメンバー３（ｎｒ１ｈ３）発現を阻害するための組成物および方法 | |
| EP4678747A2 (en) | Double-stranded rnai agents for targeting and regulating hbv gene expression, and a use thereof | |
| WO2026037284A1 (en) | Modified dsrna molecules | |
| JP2026509929A (ja) | 改善された遺伝子サイレンシングのための組成物及び方法 | |
| WO2025264546A1 (en) | Lipid-polynucleic acid conjugate compositions and uses thereof | |
| WO2022250050A1 (ja) | ｓｃｐＢＮＡ又はＡｍＮＡを含むヘテロ核酸 |